Lipocine (LPCN) Stock Statistics & Valuation Metrics

Lipocine has a market cap or net worth of $53.58M. The enterprise value is $35.55M.

Lipocine has 7,299,687 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lipocine’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -71.64%.

The current PE Ratio of Lipocine is ―. Lipocine’s PEG ratio is 0.00004.

In the last 12 months, Lipocine had revenue of 1.98M and earned -9.63M in profits. Earnings per share was -1.77.

In the last 12 months, operating cash flow was -9.76M and capital expenditures 4.00, giving a free cash flow of -9.76M billion.

Lipocine pays an annual dividend of ―, resulting in a dividend yield of ―

Lipocine upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Lipocine as a current ratio of 6.68, with Debt / Equity ratio of 0.00%

In the past 12 months, Lipocine has paid 200.00 in taxes.

Lipocine EV to EBITDA ratio is -3.74, with an EV/FCF ratio of -3.95.

Lipocine has $14.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of $14.93M billion.

Gross margin is -8.86%, with operating margin of -524.69%, and net profit margin of -487.06%.

The average price target for Lipocine is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy